Overview

Prevention of Thromboembolic Events in Total Knee Replacement Patients

Status:
Withdrawn

Trial end date:
2020-04-17

Target enrollment:

Participant gender:

Summary

The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Enoxaparin